Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingWages, Salaries and Other
Ratios

Marimed (MRMD) EBIAT (2016 - 2025)

Historic EBIAT for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to -$2.9 million.

  • Marimed's EBIAT fell 19304.17% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year decrease of 2490.44%. This contributed to the annual value of -$12.2 million for FY2024, which is 2412.2% up from last year.
  • According to the latest figures from Q3 2025, Marimed's EBIAT is -$2.9 million, which was down 19304.17% from -$1.3 million recorded in Q2 2025.
  • Over the past 5 years, Marimed's EBIAT peaked at $7.6 million during Q2 2021, and registered a low of -$10.2 million during Q4 2023.
  • Over the past 5 years, Marimed's median EBIAT value was -$1.0 million (recorded in 2024), while the average stood at -$863421.1.
  • Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 72510.45% in 2021, then plummeted by 32003.08% in 2025.
  • Quarter analysis of 5 years shows Marimed's EBIAT stood at -$6.4 million in 2021, then soared by 174.32% to $4.8 million in 2022, then crashed by 313.73% to -$10.2 million in 2023, then increased by 21.64% to -$8.0 million in 2024, then soared by 62.98% to -$2.9 million in 2025.
  • Its EBIAT was -$2.9 million in Q3 2025, compared to -$1.3 million in Q2 2025 and -$5.5 million in Q1 2025.